Share this article
Share this article
The approval of Ilaris (canakinumab) in the treatment of adult-onset Still s disease (AOSD) brings hope for Canadians living with this rare, debilitating, and sometimes life-threatening inflammatory disorder.
Ilaris, an interleukin-1 beta inhibitor, provides a new mode of treatment for this disease
which previously had limited options.
1,2
DORVAL, QC, April 29, 2021 /CNW Telbec/ - Novartis Pharmaceuticals Canada Inc. is pleased to announce that Health Canada has approved Ilaris
® (canakinumab) for the treatment of active Still s disease, including adult-onset Still s disease (AOSD)
1. AOSD is a rare form of inflammatory arthritis that can be a complex disease with variable presentation and potentially life-threatening complications
Novartis in Canada named a Top 50 Best Workplace™ in the country yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Pharma Companies Seeking to Improve Health Outcomes With Innovative Products
- FN Media Group Presents Microsmallcap.com Market Commentary
News provided by
Share this article
Share this article
NEW YORK, April 8, 2021 /PRNewswire/ Conditions such as HIV, asthma, hepatitis, and severe migraines affect the quality of life of those living with these conditions. These conditions require patients to take preventive or control medication to avoid adverse developments due to the conditions. Pharmaceutical companies like
Valeo Pharma Inc. (CSE:VPH) (OTCQB:VPHIF), Pfizer (NYSE:PFE), AbbVie Inc. (NYSE:ABBV), and
Gilead Sciences (NASDAQ:GILD) have taken note of the challenges of managing these conditions and the potential of exacerbations and worse outcomes for people with poorly managed conditions. They have developed drugs and advanced care therapies that improve the management of these conditions. These developments in the pharmaceutical industry open up a potential market op
Valeo Pharma Reports its First Quarter 2021 Results and Highlights newswire.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswire.ca Daily Mail and Mail on Sunday newspapers.
Alberta provides treatment for genetic disorder
Poll
Yes
By Dale Woodard on January 30, 2021.
Alberta families of children with a rare genetic disorder received some good news on the treatment front Wednesday when it was announced children suffering from spinal muscular atrophy may now be eligible to receive funding for gene replacement therapy treatment. Alberta’s government is working with Novartis Pharmaceuticals Canada Inc. to provide interim patient access to Zolgensma. Spinal muscular atrophy is a rare and progressive genetic disorder that causes muscle wasting. Alberta children with SMA and who may become ineligible for the treatment while waiting for the final approval processes to be completed will be considered for funding on a case-by-case basis.